EHA 2017

6:07
A CRISPR approach to hematological research
Sven Lundberg
5:27
Two is better than one: drug synergy in relapsed/refractory NHL
Paul A. Hamlin
2:34
Key topics on AML at EHA 2017
Oliver Ottmann
0:52
T-cell therapy: successes and unmet needs
David Maloney
2:31
The ideal sequence: treating patients with CLL
Florence Cymbalista
2:00
What are the non-drug-related aspects of patient care?
Claire Harrison
2:19
The potential of momelotinib against myeloproliferative malignancies
Claire Harrison
4:34
What is the focus of EHA?
Shai Izraeli
2:04
Venetoclax and ibrutinib: the future for treating WM
Steven Treon
0:53
NEOD001 in amyloidosis
Morie Gertz
4:16
Can a epoetin biosimilar be used to treat chemotherapy-induced anemia?
Paul Cornes
2:24
Future challenges facing hematological malignancies
Robin Foà
3:13
EHA 2017: keeping in touch with the world
Robin Foà
3:00
The joint symposium run by EHA and ESH
Steve Johnson
3:39
Novel agents for myeloma related bone disease
Evangelos Terpos
4:26
Is denosumab superior to zoledronic acid in the treatment of bone metastases in MM?
Evangelos Terpos
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals